Digital Therapeutics

The Digital Therapeutics Advisory Group is focused on developing resources for payers on when they should evaluate products, what manufacturers should communicate, and understanding how Digital Therapeutics are included in drug compendia. This advisory group is active from March 2022-February 2023.

On May 18, 2022, AMCP hosted Legislative Days where AMCP members and the AMCP Policy and Government Relations team met virtually with U.S. Senators and Representatives to advocate for AMCP's top policy priorities. Learn more about the role Legislative Days plays in achieving our mission to improve patient health by ensuring access to high-quality, cost-effective medications and other therapies.

AMCP thanks the Senators and Congressmen on their leadership and introduction of the bipartisan, bicameral act.

AMCP applauds Senators Moore Capito (R-WV) and Shaheen (D-NH) and Congressmen Thompson (D-CA-5) and McKinley (R-WV-1) on the introduction of the bipartisan Access to Prescription Digital Therapeutics Act.

Forum participants discussed various key components to better support appropriate and evidence-based coverage decisions for digital therapeutics.

AMCP webinar that reviewed proceedings from this Partnership Forum.

AMCP webinar that reviewed proceedings from this Partnership Forum.

Digital therapeutics: What are they, and where do they fit into pharmacy and medical benefits? Learn more in this blog post from AMCP CEO Susan A. Cantrell, RPh, CAE.

AMCP last week gathered a group of diverse health care stakeholders to discuss the challenges and opportunities of ensuring patient access to a category of emerging therapies known as “digital therapeutics,” which have the potential to treat a wide range of diseases and medical conditions.